Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Nathalie Carrier¹, Sophie Roux², Hugues Allard-Chamard² and Gilles Boire³, ¹Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ²Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ³Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
Abstract Number: 0904 • ACR Convergence 2022
Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis
Alberto Sulli¹, Guglielmo Bruzzone¹, Paolo Vittoriano Clini¹, Luca Carmisciano², Tamara Vojinovic¹, andrea cere¹, sabrina Paolino¹, Emanuele Gotelli¹ and Maurizio Cutolo¹, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ²Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, Italy
Background/Purpose: Small joints of hands in rheumatoid arthritis (RA) are usually involved from the beginning, slowing the fine finger movements and inducing progressive reduction in…
Abstract Number: 0920 • ACR Convergence 2022
Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Ji-Won Kim¹, Sun-Kyung Lee², Ju-Yang Jung¹, Chang-Hee Suh³, Kichul Shin⁴ and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Hanyang university, Seoul, Republic of Korea, ³Ajou University Hospital, Suwon, Republic of Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The aim was to evaluate long-term drug retention and safety of biologic (bDMARDs) or targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) and to identify…
Abstract Number: 0937 • ACR Convergence 2022
Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response
Emanuele Bozzalla Cassione¹, Iolanda Mazzucchelli², Terenzj Luvaro², Blerina Xoxi², Ludovico De Stefano², Garifallia Sakellariou², Silvia Grignaschi², Mehrad Mansoubi², Serena Bugatti², Carlomaurizio Montecucco² and Antonio Manzo³, ¹University of Pavia, IRCCS Policlinico San Matteo Foundation, Milano, Milan, Italy, ²University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, ³IRCCS Policlinico San Matteo Foundation/University of Pavia, Pavia, Pavia, Italy
Background/Purpose: Drug-free (DF) remission, as a putative proxy of cure, has recently gained the attention of the scientific community as a desirable new target of…
Abstract Number: 1148 • ACR Convergence 2022
GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA
Marc Maurits¹, lydia Abasolo Alcazar², Erik van den Akker³, Johan Askling⁴, Anne Barton⁵, Stephan Blüml⁶, Stephan Böhringer⁷, Andrew Cope⁸, Paul Emery⁹, Stephen Eyre⁵, Priya Gaddi⁵, Isidoro Gonzalez¹⁰, Carl Goodyear¹¹, Annette van der Helm-van Mil¹², Xinli Hu¹³, Tom Huizinga³, John D Isaacs¹⁴, Scott Jelinsky¹³, Martina Johannesson⁴, Samantha Jurado Zapata³, Changlin Ke³, Lars Klareskog⁴, Dennis Lendrem¹⁵, Myles Lewis¹⁶, Mingdong Liu³, Paul Martin¹⁷, Iain B McInnes¹⁸, Raphael Micheroli¹⁹, Ann Morgan²⁰, Fraser Morton¹¹, Najib Naamane¹⁵, Gisela Orozco⁵, Caroline Ospelt²¹, Leonid Padyukov⁴, Caron Paterson¹¹, Darren Plant⁵, Duncan Porter²², Arthur Pratt²³, Soumya Raychaudhuri²⁴, Louise Reynard¹⁵, Luis Rodriguez-Rodriguez²⁵, Daniela Sieghart²⁶, Paul Studenic⁶, John Taylor²⁷, René Toes³, Marloes Verstappen³, Suzanne Verstappen⁵, Helga Westerlind⁴, Aaron Winkler¹³ and Rachel Knevel³, ¹LUMC, Leiden, Netherlands, ²IDISSC Hospital Clinico San Carlos, Madrid, Spain, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Medical University of Vienna, Vienna, Austria, ⁷Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ⁸King's College London, Surrey, United Kingdom, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹⁰Hospital Universitario de La Princesa, Madrid, Spain, ¹¹University of Glasgow, Glasgow, Scotland, United Kingdom, ¹²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ¹³Pfizer Inc., Cambridge, MA, ¹⁴Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ¹⁵Newcastle University, Newcastle, United Kingdom, ¹⁶Queen Mary University of London, London, United Kingdom, ¹⁷The University of Manchester, Oberhaching, Germany, ¹⁸Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹⁹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ²⁰University of Leeds, Leeds, United Kingdom, ²¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²²Gartnavel General Hospital, Bearsden, United Kingdom, ²³Newcastle University, Newcastle upon Tyne, United Kingdom, ²⁴Brigham and Women's Hospital, Boston, MA, ²⁵Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, ²⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²⁷University of Leeds, Euclid, OH
Background/Purpose: In order to understand the genetic factors that lead to early remission in RA, we performed a GWAS to uncover important biological pathways.Methods: We…
Abstract Number: 1262 • ACR Convergence 2022
Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis
Irina Gessl¹, Thomas Deimel¹, Paul Studenic¹, Giorgio Tamborrini², Pascal Zufferey³, Daniel Aletaha⁴, Burkhard Moeller⁵ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Ultrasound Center and Institute for Rheumatology, Zürich, Switzerland, ³HFR, Fribourg, Switzerland, ⁴Medical University Vienna, Wien, Austria, ⁵Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: Musculoskeletal ultrasound (US) has been reported to predict radiographic progression in rheumatoid arthritis (RA). The aim of the study was to test the predictive…
Abstract Number: 1388 • ACR Convergence 2022
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
Anthony Dolomisiewicz¹, Hanifah Ali², Punyasha Roul³, Yangyuna Yang¹, Grant Cannon⁴, Joshua Baker⁵, Ted Mikuls⁶, Kaleb Michaud¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, ³UNMC, Omaha, NE, ⁴Salt Lake City VA, Salt Lake city, ⁵University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Rheumatic Disease Comorbidity Index (RDCI) was designed to quantify comorbidity burden for risk stratification of health outcomes in patients with rheumatic disease. Developed…
Abstract Number: 1404 • ACR Convergence 2022
Machine Learning Model to Accurately Identify Rheumatoid Arthritis Patients Using Raw Electronic Health Record Data
Vinit Gilvaz¹, Anthony Reginato², Deepan Dalal³ and Brad Crough⁴, ¹Brown University, East Providence, RI, ²Brown University, Providence, RI, ³Brown University School of Medicine, Providence, RI, ⁴Brown Physicians Inc., Providence, RI
Background/Purpose: Patients with chronic medical conditions like rheumatoid arthritis (RA) have a wealth of clinical data stored within their electronic medical records (EMR). Artificial intelligence…
Abstract Number: 1422 • ACR Convergence 2022
Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen J. Lehman⁶, Meagan Rachich⁷, Francois Nantel⁸, A. Marilise Marrache⁹ and Odalis Asin-Milan¹⁰, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Memorial University, St. John's, NL, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Guelph, ON, Canada, ⁸Nantel MedSci Consult, Montréal, QC, Canada, ⁹Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ¹⁰Janssen Canada, Laval, QC, Canada
Background/Purpose: Although biologic use in RA has a well-characterized infections risk factor, most studies were done on 1st-generation anti-tumor necrosis factor (TNFi) drugs or post-drug…
Abstract Number: 1586 • ACR Convergence 2022
Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study
Satoshi Kubo¹, Yusuke Miyazaki², Koichi Amano³, Kiyoshi Matsui⁴, Hideto Kameda⁵, Yoshino Inoue⁶, Shingo Nakayamada⁶, Takehisa Ogura⁷, Yuko Kaneko⁸, Kunihiro Yamaoka⁹ and Yoshiya Tanaka¹⁰, ¹Department of Advanced Targeted Therapies, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ³Saitama Medical Center, Kawagoe, Japan, ⁴Hyogo College of Medicine, Nishinomiya, Japan, ⁵Toho University, Tokyo, Japan, ⁶First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Toho university, Meguro-ku, Japan, ⁸Keio University, Tokyo, Japan, ⁹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ¹⁰University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (RA).Methods: RA patients who had an inadequate response to methotrexate…
Abstract Number: 1647 • ACR Convergence 2022
Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Matched Cohort Study with Cancer Registry Linkage
Rebecca Brooks¹, Yangyuna Yang¹, Punyasha Roul², Brent Luedders¹, Namrata Singh³, Brian Sauer⁴, Grant Cannon⁵, Joshua Baker⁶, Ted Mikuls⁷ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Retired, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While patients with RA are predisposed to developing lung cancer, prior epidemiologic studies have been limited in their ability to account for potential confounders…
Abstract Number: 1743 • ACR Convergence 2022
Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment
Maria Christofi¹, Ben Mulhearn², Lysette Marshall¹, Megan Sutcliffe¹, Darren Plant¹, Kimme Hyrich¹, Ann Morgan³, Anthony Wilson⁴, John D Isaacs⁵, Soumya Raychaudhuri⁶, Anne Barton¹ and Sebastien Viatte¹, ¹The University of Manchester, Manchester, United Kingdom, ²Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University College Dublin, Dublin, Ireland, ⁵Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex immune mediated disease that affects 1% of the population. Even with modern therapeutic strategies, many patients with RA…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1963 • ACR Convergence 2022
Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
Colleen O'Neill¹ and Veena Patel², ¹Dell Medical School - UTHealth Austin, Austin, TX, ²Dell Medical School - UT Health Austin, Austin, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease (ASCVD) compared to the general population and RA is considered a…
Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Eric Malmhäll-Bah¹, Karin Andersson², Nina Oparina², Sofia Töyrä Silfverswärd³, Malin Erlandsson² and Maria Bokarewa³, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].